5250 results for "*oma"

in 17.51 milliseconds.

• IMC-F106C-101 dose escalation

  Brenetafusp is an ImmTAC bispecific (PRAME×CD3) targeting the cancer testis antigen PRAME. In this phase 1 study (NCT04262466), 126 HLA-A*02:01+ patients with advanced solid tumors received weekly IV doses from 0.3-320 mcg. The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D); additional objectives included pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity. Brenetafusp demonstrated manageable safety and preliminary efficacy in PRAME+ tumors. A phase 3 trial in metastatic cutaneous melanoma is ongoing

  Study EGAS50000001976

• RNA-seq for "A preinvasive regulatory T cell axis for lung cancer interception" paper

  Bulk RNA sequencing data generated from primary resected non-small cell lung cancer (NSCLC) tumour tissue collected through the ASCENT study (Analysis of Screen-Detected Lung Cancers’ Genomic Traits; NCT04204499). The dataset comprises tumour RNA-seq from 89 patients with CT screen-detected NSCLC, predominantly early-stage disease, including lung adenocarcinoma and lung squamous cell carcinoma. The RNA-seq data were used to characterise tumour-immune transcriptional programmes and were analysed alongside matched peripheral blood immune profiling and clinical follow-up data.

  Dataset EGAD50000002852

• LUAD RNAseq – LORD

  RNA-seq data from paired normal and adenocarcinoma lung samples obtained from 515 patients that underwent lung cancer surgery.

  Study EGAS50000001705

• LUAD RNAseq - LORD

  The Lung Oncology Research and Discovery (LORD) program is a multi-omics translational initiative aimed at advancing precision medicine in lung cancer. It builds on a lung tissue biobank and leverages biological samples collected from patients who underwent lung cancer surgery at the IUCPQ-UL (Quebec City, Canada). LORD is therefore a single-site, retrospective, case-only study. Genomic profiling of biobanked samples is ongoing, with samples being analyzed sequentially in phases defined by sample type and omic modality. For this dataset, we provide RNA-seq data from paired normal and adenocarcinoma lung samples obtained from 515 patients.

  Dataset EGAD50000002450

• Projet LORD- LUAD RNAseq data

  RNAseq data from paired samples of non affected lung parenchyma and Lung adenocarcinoma (LUAD) from 515 patients surgically intervened at the Institut universitaire de cardiologie et de pneumologie de Québec- Université Laval

  Dac EGAC50000000846

• Sequencing data for ICGC Oesophageal Adenocarcinoma tissue samples - pilot normal and pre/post-chemo

  Dataset EGAD00001000704

• Single-cell RNA sequencing of large B cell lymphoma relapsed after CAR T-cell therapy and in vitro serial killing models

  Relapsed/refractory large B-cell lymphoma (rrLBCL) following CAR T-cell therapy remains associated with a poor prognosis. Using single-cell RNA sequencing (scRNA-seq), we characterized the T-cell profiles in 7 post-CAR T rrLBCL and 5 CAR T-naïve rrLBCL, revealing dysfunctional transcriptional features in T cells after CAR T-cell therapy. In addition, the dataset includes T cell profiling of CAR T-cell products and samples obtained after serial killing assays in vitro, performed with or without supplementation with non-IL2Rα agonist pegenzileukin. These analyses demonstrated that IL-2 was the most depleted cytokine following the coculture assay.

  Study EGAS50000001982

• Single-cell RNA sequencing of large B cell lymphoma relapsed after CAR T-cell therapy and in vitro serial killing models

  Relapsed/refractory large B-cell lymphoma (rrLBCL) following CAR T-cell therapy remains associated with a poor prognosis. Using single-cell RNA sequencing (scRNA-seq), we characterized the T-cell profiles in 7 post-CAR T rrLBCL and 5 CAR T-naïve rrLBCL, revealing dysfunctional transcriptional features in T cells after CAR T-cell therapy. In addition, the dataset includes T cell profiling of CAR T-cell products and samples obtained after serial killing assays in vitro, performed with or without supplementation with non-IL2Rα agonist pegenzileukin. These analyses demonstrated that IL-2 was the most depleted cytokine following the coculture assay.

  Dataset EGAD50000002866

• MOSAIC Window Mesothelioma Data

  This dataset will include Spatial Transcriptomics from the 10x Genomics Visium SD technology, Single-Cell RNA-Seq from the 10x Genomics Chromium Flex protocol, Bulk RNA-Seq (sequenced on Illumina), WES (sequenced on Illumina), H&E, and Clinical data from 10 Mesothelioma patients. For Visium and Chromium data we are sharing the outputs of respectively Space Ranger and Cell Ranger. For Bulk RNA-Seq we are including processed files such as counts.tsv, FPKM.tsv, fusion_genes.tsv, TPM count matrix.tsv, DESeq2 count matrix.tsv, multiqc_report. For WES, we are sharing the presence or absence of single nucleotide variants (SNVs), small insertions and deletions (indels), and copy number variants (CNVs).* Researchers from private or public institutions outside the MOSAIC Consortium will be able to apply to access this data and, pending approval, use the data for their research.

  Dataset EGAD50000001706

• MOSAIC Window Glioblastoma Data

  This dataset will include Spatial Transcriptomics, Single-Cell RNA-Seq, Bulk RNA-Seq, Clinical data, WES, and H&E data from 10 Glioblastoma (GBM) Cancer patients. Researchers from private or public institutions outside the MOSAIC Consortium will be able to apply to access this data and, pending approval, use the data for their research.

  Dataset EGAD50000001352